Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

How can we improve the timeliness and quality of diagnostic assessment for children with possible autism? Qualitative findings and recommendations from a Realist Evaluation of Autism Service delivery in the United Kingdom.

Autism : the international journal of research and practice·2026
Same author

Prophylactic antibiotics to prevent chest infections in children with neurological impairment: the PARROT RCT.

Health technology assessment (Winchester, England)·2026
Same author

Immunotherapy responsive startle with antibodies to voltage gated potassium channels.

BMJ case reports·2025
Same author

Subtype-specific atypical B cell profiles in myasthenia gravis reveal distinct immunopathological pathways.

Frontiers in immunology·2025
Same author

Evolution and significance of neuronal surface autoantibodies after Japanese encephalitis.

Journal of neuroimmunology·2025
Same journal

Preface.

Handbook of clinical neurology·2026
Same journal

Foreword.

Handbook of clinical neurology·2026
Same journal

Fundus autofluorescence imaging.

Handbook of clinical neurology·2026
Same journal

The electroretinogram as a means to study the physiology of the retina.

Handbook of clinical neurology·2026
Same journal

Adaptive optics scanning light ophthalmoscopy.

Handbook of clinical neurology·2026
Same journal

Modeling the human retina in a dish: Advances and future directions.

Handbook of clinical neurology·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Autoimmune myasthenia gravis.

Sandeep Jayawant1, Jeremy Parr, Angela Vincent

  • 1Department of Paediatrics, University of Oxford, Oxford, UK.

Handbook of Clinical Neurology
|April 30, 2013
PubMed
Summary
This summary is machine-generated.

This study provides guidelines for recognizing, diagnosing, and treating juvenile myasthenia gravis, a condition affecting children that can present in generalized or ocular forms. It emphasizes distinguishing it from other neuromuscular disorders and considering perinatal conditions.

Related Experiment Videos

Last Updated: May 11, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Pediatric Neurology
  • Neuromuscular Disorders

Background:

  • Myasthenia gravis in children presents as generalized or ocular forms, with or without specific antibodies (acetylcholine receptor or muscle-specific kinase).
  • Differential diagnosis is crucial, including congenital myasthenic syndromes and other neuromuscular diseases.
  • Perinatal considerations include transient neonatal myasthenia and arthrogryposis multiplex congenita due to maternal antibodies.

Purpose of the Study:

  • To establish comprehensive guidelines for the recognition, diagnosis, and treatment of juvenile myasthenia gravis.
  • To aid clinicians in differentiating juvenile myasthenia gravis from similar pediatric neuromuscular conditions.
  • To provide a framework for managing seronegative and antibody-associated forms of the disease in children.

Main Methods:

  • Review and synthesis of existing literature on juvenile myasthenia gravis.
  • Analysis of clinical presentations, diagnostic criteria, and treatment strategies.
  • Development of evidence-based recommendations for clinical practice.

Main Results:

  • Juvenile myasthenia gravis shares similarities in presentation and treatment with adult forms.
  • Accurate diagnosis requires distinguishing it from congenital myasthenic syndromes and other neuromuscular diseases.
  • Guidelines address antibody-positive and seronegative cases, as well as perinatal conditions.

Conclusions:

  • Standardized guidelines are essential for optimal management of juvenile myasthenia gravis.
  • Early and accurate diagnosis improves patient outcomes.
  • The guidelines aim to enhance clinical decision-making for pediatric neuromuscular specialists.